ArticleCureus2025
Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of semaglutide-associated kidney injury case reports.Frontiers in medicine · 2026Pooled it
- Pooled it
- Perioperative Management of Patients using GLP-1 Receptor Agonists Current Evidence, Risks, and Practical Recommendations-A Narrative Review.Turkish journal of anaesthesiology and reanimation · 2026Article
- GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications.Annals of medicine and surgery (2012) · 2026Article
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroparesis is a chronic disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms such as nausea, vomiting, and abdominal discomfort. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes, can slow gastric motility and induce gastroparesis. We present a case of a 48-year-old woman with type 2 diabetes, who developed persistent nausea and vomiting after resuming semaglutide at 2 mg subcutaneously once weekly without following the recommended stepwise titration schedule (typically initiated at 0.25 mg weekly with gradual escalation). Shortly thereafter, she developed acute kidney injury secondary to dehydration. Imaging also demonstrated left-sided colitis, for which she received antibiotic therapy. Gastroparesis was suspected due to semaglutide use. Treatment with metoclopramide and cessation of semaglutide resulted in symptom resolution and recovery. Thus, semaglutide-induced gastroparesis should be considered in diabetic patients presenting with gastrointestinal symptoms, especially with rapid dose escalation. Early recognition and discontinuation of the drug can lead to swift symptom resolution and prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.